vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Penguin Solutions, Inc.（PENG）财务数据对比。点击上方公司名可切换其他公司
Penguin Solutions, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.9倍（$343.1M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 1.5%，领先11.8%），Penguin Solutions, Inc.同比增速更快（0.6% vs -1.8%），Penguin Solutions, Inc.自由现金流更多（$28.2M vs $24.6M），过去两年Penguin Solutions, Inc.的营收复合增速更高（11.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
企鹅解决方案公司旗下的兰波集团以拉姆齐解决方案品牌开展业务，是一家美国企业，业务涵盖个人理财、领导力发展、人际关系管理与职业发展相关产品与服务。该公司由戴夫·拉姆齐与妻子莎伦于1991年创立，总部位于田纳西州富兰克林。
AMPH vs PENG — 直观对比
营收规模更大
PENG
是对方的1.9倍
$183.1M
营收增速更快
PENG
高出2.4%
-1.8%
净利率更高
AMPH
高出11.8%
1.5%
自由现金流更多
PENG
多$3.6M
$24.6M
两年增速更快
PENG
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $343.1M |
| 净利润 | $24.4M | $5.3M |
| 毛利率 | 46.8% | 28.0% |
| 营业利润率 | 19.4% | 5.7% |
| 净利率 | 13.3% | 1.5% |
| 营收同比 | -1.8% | 0.6% |
| 净利润同比 | -35.7% | 1.0% |
| 每股收益（稀释后） | $0.51 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPENG
| Q4 25 | $183.1M | $343.1M | ||
| Q3 25 | $191.8M | $337.9M | ||
| Q2 25 | $174.4M | $324.3M | ||
| Q1 25 | $170.5M | $365.5M | ||
| Q4 24 | $186.5M | $341.1M | ||
| Q3 24 | $191.2M | $284.8M | ||
| Q2 24 | $182.4M | $300.6M | ||
| Q1 24 | $171.8M | — |
净利润AMPHPENG
| Q4 25 | $24.4M | $5.3M | ||
| Q3 25 | $17.4M | $9.4M | ||
| Q2 25 | $31.0M | $2.7M | ||
| Q1 25 | $25.3M | $8.1M | ||
| Q4 24 | $38.0M | $5.2M | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $37.9M | $5.6M | ||
| Q1 24 | $43.2M | — |
毛利率AMPHPENG
| Q4 25 | 46.8% | 28.0% | ||
| Q3 25 | 51.4% | 28.6% | ||
| Q2 25 | 49.6% | 29.3% | ||
| Q1 25 | 50.0% | 28.6% | ||
| Q4 24 | 46.5% | 28.7% | ||
| Q3 24 | 53.3% | 28.8% | ||
| Q2 24 | 52.2% | 29.6% | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHPENG
| Q4 25 | 19.4% | 5.7% | ||
| Q3 25 | 13.2% | 3.7% | ||
| Q2 25 | 24.2% | 3.0% | ||
| Q1 25 | 21.9% | 5.1% | ||
| Q4 24 | 24.2% | 5.1% | ||
| Q3 24 | 29.8% | -1.2% | ||
| Q2 24 | 30.3% | 3.8% | ||
| Q1 24 | 27.9% | — |
净利率AMPHPENG
| Q4 25 | 13.3% | 1.5% | ||
| Q3 25 | 9.0% | 2.8% | ||
| Q2 25 | 17.8% | 0.8% | ||
| Q1 25 | 14.8% | 2.2% | ||
| Q4 24 | 20.4% | 1.5% | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 20.8% | 1.9% | ||
| Q1 24 | 25.1% | — |
每股收益（稀释后）AMPHPENG
| Q4 25 | $0.51 | $0.04 | ||
| Q3 25 | $0.37 | $0.10 | ||
| Q2 25 | $0.64 | $-0.01 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $0.10 | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | $0.10 | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $461.5M |
| 总债务越低越好 | $608.7M | $462.3M |
| 股东权益账面价值 | $788.8M | $389.7M |
| 总资产 | $1.6B | $1.6B |
| 负债/权益比越低杠杆越低 | 0.77× | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资AMPHPENG
| Q4 25 | $282.8M | $461.5M | ||
| Q3 25 | $276.2M | $453.8M | ||
| Q2 25 | $231.8M | $735.5M | ||
| Q1 25 | $236.9M | $647.0M | ||
| Q4 24 | $221.6M | $393.7M | ||
| Q3 24 | $250.5M | $389.5M | ||
| Q2 24 | $217.8M | $467.5M | ||
| Q1 24 | $289.6M | — |
总债务AMPHPENG
| Q4 25 | $608.7M | $462.3M | ||
| Q3 25 | $608.6M | $461.8M | ||
| Q2 25 | $607.7M | $659.5M | ||
| Q1 25 | $603.9M | $658.8M | ||
| Q4 24 | $601.6M | $658.1M | ||
| Q3 24 | $596.4M | $657.3M | ||
| Q2 24 | $586.9M | $667.0M | ||
| Q1 24 | $594.0M | — |
股东权益AMPHPENG
| Q4 25 | $788.8M | $389.7M | ||
| Q3 25 | $776.7M | $394.2M | ||
| Q2 25 | $757.5M | $584.8M | ||
| Q1 25 | $751.3M | $602.5M | ||
| Q4 24 | $732.3M | $400.4M | ||
| Q3 24 | $727.7M | $391.4M | ||
| Q2 24 | $713.3M | $423.4M | ||
| Q1 24 | $672.4M | — |
总资产AMPHPENG
| Q4 25 | $1.6B | $1.6B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | — |
负债/权益比AMPHPENG
| Q4 25 | 0.77× | 1.19× | ||
| Q3 25 | 0.78× | 1.17× | ||
| Q2 25 | 0.80× | 1.13× | ||
| Q1 25 | 0.80× | 1.09× | ||
| Q4 24 | 0.82× | 1.64× | ||
| Q3 24 | 0.82× | 1.68× | ||
| Q2 24 | 0.82× | 1.58× | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $31.1M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $28.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 8.2% |
| 资本支出强度资本支出/营收 | 4.5% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.35× | 5.89× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $116.3M |
8季度趋势，按日历期对齐
经营现金流AMPHPENG
| Q4 25 | $32.9M | $31.1M | ||
| Q3 25 | $52.6M | $-70.4M | ||
| Q2 25 | $35.6M | $92.8M | ||
| Q1 25 | $35.1M | $72.9M | ||
| Q4 24 | $29.0M | $13.8M | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $69.1M | $57.9M | ||
| Q1 24 | $55.3M | — |
自由现金流AMPHPENG
| Q4 25 | $24.6M | $28.2M | ||
| Q3 25 | $47.2M | $-73.4M | ||
| Q2 25 | $25.0M | $90.9M | ||
| Q1 25 | $24.4M | $70.5M | ||
| Q4 24 | $16.6M | $12.0M | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | $48.9M | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHPENG
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | -21.7% | ||
| Q2 25 | 14.3% | 28.0% | ||
| Q1 25 | 14.3% | 19.3% | ||
| Q4 24 | 8.9% | 3.5% | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | 16.3% | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHPENG
| Q4 25 | 4.5% | 0.8% | ||
| Q3 25 | 2.8% | 0.9% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 0.6% | ||
| Q4 24 | 6.7% | 0.5% | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 5.1% | — |
现金转化率AMPHPENG
| Q4 25 | 1.35× | 5.89× | ||
| Q3 25 | 3.03× | -7.47× | ||
| Q2 25 | 1.15× | 34.88× | ||
| Q1 25 | 1.39× | 9.02× | ||
| Q4 24 | 0.76× | 2.65× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 10.30× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PENG
| Integrated Memory Segment | $171.6M | 50% |
| Advanced Computing Segment | $115.7M | 34% |
| Optimized LED Segment | $55.7M | 16% |
